Results 1 to 10 of about 42,587 (212)

Nasal primary anaplastic lymphoma kinase-negative anaplastic large cell lymphoma with fungal infection: A case report [PDF]

SAGE Open Medical Case Reports
This report pertains to a case of nasal primary anaplastic lymphoma kinase-negative anaplastic large cell lymphoma, which was complicated by a fungal infection. The patient, a 66-year-old female, experienced pain in the left side of her face for 1 month.
Yun Huang, Liang Luo, Yi-bin Liu, Xin-Tao Wang, Long-Gui You, Huan Li   +5 more
doaj   +2 more sources

Pulmonary Spindle Cell Carcinoma Presenting Anaplastic Lymphoma Kinase Rearrangement

Case Reports in Oncology, 2023
Pulmonary spindle cell carcinoma is a subtype of pulmonary sarcomatoid carcinoma and a very rare tumor type with a poor prognosis. A few case reports have documented patients with pulmonary sarcomatoid carcinoma with anaplastic lymphoma kinase ...
Kei Sonehara, Shuhei Nozawa, Yusuke Suzuki, Taisuke Araki, Masamichi Komatsu, Kazunari Tateishi, Masayuki Hanaoka   +6 more
doaj   +1 more source

Identification of Mutation in Neuroblastoma on the Point of Molecular Heterogeneity

Technology in Cancer Research & Treatment, 2023
Background and Aim In neuroblastoma, anaplastic lymphoma kinase mutations have recently received attention as molecular targets for the treatment of neuroblastoma, as 6% to 10% of patients with neuroblastoma have anaplastic lymphoma kinase mutations ...
Tekincan Çağrı Aktaş MD, PhD, Deniz Kızmazoğlu MD, PhD, Safiye Aktaş MD, PhD, Özde Elif Gökbayrak MSc, PhD, Efe Serinan MSc, PhD, Aylin Erol MSc, PhD, Zekiye Altun MD, PhD, Hongling Yuan MD, MSc, Hatice Nur Olgun MD   +8 more
doaj   +1 more source

Treatment of anaplastic lymphoma kinase-positive lung adenocarcinoma with pemetrexed and carboplatin after crizotinib failure and significant liver dysfunction; a case report

Cancer Treatment and Research Communications, 2021
Tyrosine kinase inhibitors are the first-line treatment for Anaplastic Lymphoma Kinase-positive lung adenocarcinomas. However, chemotherapy is still an option in patients who are unresponsive or intolerant of tyrosine kinase inhibitors.
Oranus Mohammadi, Kayla Haines, Mohammad Jahanzeb   +2 more
doaj   +1 more source

Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report

Journal of Medical Case Reports, 2022
Background Anaplastic lymphoma kinase tyrosine kinase inhibitors are standard therapeutic agents prescribed for anaplastic lymphoma kinase-positive non-small cell lung cancer, and treatment with these agents has been shown to contribute to long-term ...
Fumihiro Kashizaki, Arihito Tanaka, Yasutomo Sekido   +2 more
doaj   +1 more source

Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer

Frontiers in Pharmacology, 2023
In non-small cell lung cancer (NSCLC), two key genetic alterations, epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements, are commonly believed to be mutually exclusive.
Haoyue Hu, Songtao Tan, Songtao Tan, Meng Xie, Peng Guo, Qiang Yu, Qiang Yu, Juan Xiao, Kangrui Zhao, Qiong Liao, Yi Wang   +10 more
doaj   +1 more source

Expression of CD8 is associated with non-common type morphology and outcome in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma

Haematologica, 2013
Anaplastic lymphoma kinase-positive anaplastic large T-cell lymphoma is characterized by morphological variability. Morphological variants (non-common subtype) are associated with a poor outcome.
Dmitriy Abramov, Ilske Oschlies, Martin Zimmermann, Dmitriy Konovalov, Christine Damm-Welk, Wilhelm Wössmann, Wolfram Klapper   +6 more
doaj   +1 more source

An autopsy case of anaplastic lymphoma kinase-positive lung cancer exacerbated in a short period of time: a case report

Journal of Medical Case Reports, 2019
Background Anaplastic lymphoma kinase-positive lung cancer is a form of lung cancer that accounts for approximately 5% of non-small cell lung cancers.
Masahide Takeda, Kazuhiro Sato, Sho Sakamoto, Maya Suzuki, Yuka Izumiya, Naho Kumagai, Kazuhisa Sudo, Yuji Okuda, Mariko Asano, Masaaki Sano, Yasufumi Omori, Katsutoshi Nakayama   +11 more
doaj   +1 more source

Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report [PDF]

, 2013
BACKGROUND: Anaplastic lymphoma kinase-positive non-small cell lung carcinoma patients are generally highly responsive to the dual anaplastic lymphoma kinase and MET tyrosine kinase inhibitor crizotinib.
Birgit G Skov, Charlotte K Rask, Edyta M Urbanska, Eric Santoni-Rugiu, Henrik H Rossing, Jens Sørensen, Junia C Costa, Linea C Melchior, Morten Grauslund   +8 more
core   +1 more source

Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome [PDF]

, 2017
Background: Neuroblastoma is an aggressive childhood malignancy of the sympathetic nervous system. Despite multi-modal therapy, survival of high-risk patients remains disappointingly low, underscoring the need for novel treatment strategies.
Cannoodt, Robrecht, Claeys, Shana, De Preter, Katleen, Denecker, Geertrui, Durinck, Kaat, Kumps, Candy, Speleman, Franki   +6 more
core   +3 more sources